Improving Fairness in Director Appointments and Compensation through the Nomination and Compensation Committee
First written in FY2022. 6 of 8 entries say "Advanced", first in FY2023. Latest entry: 2026-09-10.
- 2026-09-10Advancedwww.yakuji.co.jp
「At its Nominating Committee and Board of Directors meetings on the 8th, メディパルホールディングス decided that, effective 1 October, Representative Director and President Watanabe Shuichi (渡辺 秀一) will change from representative director and president to representative director and chairman, while Imagawa Kuniaki (今川 国明), senior managing director in charge of the pharmaceutical business and representative director and president of メディセオ, will become representative director and president.」
The Nominating Committee's consideration of succession planning and the change in president progressed to specific personnel decisions: the appointment of a new president and the change of the current president to chairman, effective 1 October. - FY2026AdvancedAnnual report
「The activities of the Nomination and Compensation Committee during the fiscal year were as follows. 1. Regarding nominations, the committee deliberated on and submitted recommendations to the Board of Directors concerning (1) candidates for directors at the June 2025 Annual General Meeting of Shareholders, (2) the succession planning process, (3) interviews with succession candidates and (4) candidates for new directors, among other matters.」
The Nomination and Compensation Committee deliberated on and submitted recommendations concerning succession-related matters, including the succession planning process and interviews with candidates. - FY2025AdvancedAnnual report
「The activities of the Nomination and Compensation Committee during the fiscal year were as follows. 1. Regarding nominations, the committee deliberated on and submitted recommendations to the Board of Directors concerning (1) candidates for directors at the June 2024 Annual General Meeting of Shareholders, (2) the succession plan and officer appointment process, (3) the committee's views on nominations and (4) candidates for new directors and new outside Audit & Supervisory Board members, among other matters. 2. Regarding compensation, the committee deliberated on and submitted recommendations to the Board of Directors concerning (1) executive bonuses paid in June 2024, (2) compensation levels and the pay ratio, (3) the committee's views on compensation and (4) a review of Audit & Supervisory Board member compensation, among other matters.」
The Nomination Committee and Compensation Committee each met 4 times and deliberated on and submitted recommendations concerning succession plans, officer appointments, compensation levels, the pay ratio and Audit & Supervisory Board member compensation, among other matters. - FY2024AdvancedAnnual report
「Regarding matters that have been under consideration, including (1) a review of director compensation, covering total compensation, evaluation criteria and the directors subject to compensation, as well as the introduction of a stock-based compensation plan, (2) the composition of the Board of Directors and (3) a succession development plan, we will continue discussions and further expand opportunities to exchange views with outside officers on governance.」
The Nomination and Compensation Committee announced a policy of expanding its scope of consideration to include director compensation, stock-based compensation plans, Board composition and succession development plans, while expanding exchanges of views with outside officers. - FY2023AdvancedAnnual report
「The activities of the Nomination and Compensation Committee during the fiscal year were as follows. 1. Regarding nominations, the committee deliberated on (1) measures to strengthen compliance, including the establishment of a code of conduct for officers, and (2) candidates for directors at the June 2023 Annual General Meeting of Shareholders, among other matters, and submitted its recommendations to the Board of Directors. 2. Regarding compensation, the committee deliberated on executive bonuses paid in June 2023 and other matters, and submitted its recommendations to the Board of Directors.」
Regarding the Nomination and Compensation Committee introduced in fiscal 2022, the Nomination Committee met 6 times and the Compensation Committee met 2 times to deliberate on and submit recommendations concerning measures to strengthen compliance, director candidates, executive bonuses and other matters. - FY2022First statedAnnual report
「We established the voluntary Nomination and Compensation Committee as an advisory body to the Board of Directors, with the aim of strengthening fairness, transparency and objectivity in matters including the nomination and compensation of directors and enhancing corporate governance. The Nomination and Compensation Committee consists of 3 or more members selected by resolution of the Board of Directors. More than half of its members are outside directors, and the committee chair is an outside director.」
We disclosed for the first time as an independent theme the framework for improving the fairness, transparency and objectivity of nomination and compensation procedures, comprising a Nomination and Compensation Committee established as an advisory body to the Board of Directors, with 3 or more members, a majority of outside directors and an outside director as chair.